Solventum Corporation (SOLV), based in Maplewood, Minnesota, is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs. With a market cap of $12 billion, the company’s broad portfolio of solutions leverages material and data science, clinical research, and digital capabilities. Solventum operates in separation and purification, health information, medical solutions, medical device component, and oral care market. The leading global healthcare company is expected to announce its fiscal first-quarter earnings for 2026 after the market closes on Tuesday, May 5.
Ahead of the event, analysts expect SOLV to report a profit of $1.35 per share on a diluted basis, up marginally from $1.34 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For the full year, analysts expect SOLV to report EPS of $6.50, up 6.4% from $6.11 in fiscal 2025. Its EPS is expected to rise 8% year over year to $7.02 in fiscal 2027.
www.barchart.comSOLV stock has underperformed the S&P 500 Index’s ($SPX) 35% gains over the past 52 weeks, with shares up 6.4% during this period. Similarly, it underperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 8.4% gains over the same time frame.
www.barchart.comOn Feb. 26, SOLV shares closed up by 2.5% after reporting its Q4 results. Its adjusted EPS of $1.57 topped Wall Street expectations of $1.50. The company’s revenue was $2 billion, exceeding Wall Street forecasts of $1.97 billion. SOLV expects full-year adjusted EPS in the range of $6.40 to $6.60.
Analysts’ consensus opinion on SOLV stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 14 analysts covering the stock, six advise a “Strong Buy” rating, six give a “Hold,” and two recommend a “Strong Sell.” SOLV’s average analyst price target is $87.08, indicating a potential upside of 26% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Is a Giant Short Squeeze in Allbirds Stock Brewing Before May? 2 Tech Stock Analysts Believe Can Bounce 70% or More Over the Next 12 Months TSLA Stock: 4 Key Things to Watch When Tesla Reports Q1 Earnings Should You Buy AMD Stock Before Earnings on May 5? GF Securities Says Yes.